NCT07339059 2026-04-09
Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Henry Ford Health System
Phase 2 Recruiting
Clinical Trials
8 trialsNCT07438600 2026-03-27
TianjinCIH
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05633667 2026-03-17
VELOCITY-Lung
Gilead Sciences
Phase 2 Recruiting
NCT05186974 2026-02-11
EVOKE-02
Gilead Sciences
Phase 2 Active not recruiting
NCT07393555 2026-02-06
Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Not yet recruiting
NCT06055465 2025-05-15
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
Chinese University of Hong Kong
Phase 2 Recruiting
NCT06401824 2025-05-06
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Maastricht University Medical Center
Phase 2 Recruiting
NCT06667167 2025-01-17
First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy
Shaare Zedek Medical Center
Phase 2 Recruiting